Altamira's nanoparticle platform passes tests
Altamira Therapeutics Ltd., a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, announced that its nanoparticle-based delivery platform was successfully tested also for circular mRNA
In vitro experiments demonstrated successful transfection of cells and significantly higher protein expression than with linear mRNA, based on which the Company has filed a provisional patent application with the United States Patent Office . Altamira will start offering its platform to biotech and pharma companies for use with circular RNA under the CycloPhore label, complementing its offerings for siRNA (OligoPhore) and mRNA (SemaPhore).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins